Candida biomarkers in patients with candidaemia and bacteraemia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objectives: Microbiological strategies are necessary to help clinicians discontinue empirical antifungal therapy in patients with suspected invasive candidiasis. Culture methods and biomarkers each show low sensitivity. We analysed the value of combining different biomarkers as a decision-making tool for discontinuing empirical antifungal treatment. Methods: We studied stored serum samples from 31 patients with candidaemia (Candida albicans 40%, Candida tropicalis 20%, Candida parapsilosis 18%, Candida glabrata 12% and other 10%) and 50 patients with bacteraemia at Gregorio Marañón Hospital, Madrid, Spain. C. albicans germ tube antibody (CAGTA), mannan antigens (MN), antimannan antibodies (AMN) and (1→3)-β-d-glucan (BDG) were assayed using the manufacturer's and alternative cut-offs to improve the accuracy of the tests. Results: The sensitivity of the biomarkers when used alone was low (58%−84%), but specificity was high (65.8%−92.0%). The best combinations were CAGTA and BDG using cut-offs of 1/80 and 80 pg/mL, respectively (sensitivity 96.8% and specificity 84%), and CAGTA and MN using cut-offs of 1/80 and 75 pg/mL, respectively (sensitivity 93.5% and specificity 86.0%). The sensitivity of both combinations was 100% for C. albicans, C. tropicalis and C. parapsilosis, but only combinations including BDG detected Candida krusei. The negative predictive values (NPVs) of both combinations were, respectively, 97.7% and 95.6% (prevalence of candidaemia, 23.6%). For a prevalence of candidaemia of 5% and 10%, the NPV reached 99.8% and 99.6%. Conclusions: The combinations of CAGTA and BDG or CAGTA and MN had a very high NPV at the alternative cut-offs and could be used in antifungal stewardship programmes as a decision-making tool for discontinuing unnecessary empirical therapy in patients with suspected candidaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Candida albicans pathogenicity mechanisms
Mayer, F. L., Wilson, D., & Hube, B. (2013) · Virulence · doi:10.4161/viru.22913 · Cited by 1,848
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Clancy, C. J., & Nguyen, M. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit006 · Cited by 688
Saville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655
ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12038 · Cited by 386
Mikulska, M., Calandra, T., Sanguinetti, M., Poulain, D., Viscoli, C., & the Third European Conference on Infections in Leukemia Group (2010) · Critical Care · doi:10.1186/cc9365 · Cited by 319
Nguyen, M. H., Wissel, M. C., Shields, R. K., Salomoni, M. A., Hao, B., Press, E. G., Shields, R. M., Cheng, S., Mitsani, D., Vadnerkar, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis200 · Cited by 290
Marchetti, O., Lamoth, F., Mikulska, M., Viscoli, C., Verweij, P., Bretagne, S., & Groups, A. T. E. C. O. I. I. L. (. L. W. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.178 · Cited by 275
Cited by
Dadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., & Dhama, K. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.028 · Cited by 332
Bassetti, M., Azoulay, E., Kullberg, B.-J., Ruhnke, M., Shoham, S., Vazquez, J., Giacobbe, D. R., & Calandra, T. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1751 · Cited by 327
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients
Martin-Loeches, I., Antonelli, M., Cuenca-Estrella, M., Dimopoulos, G., Einav, S., De Waele, J. J., Garnacho-Montero, J., Kanj, S. S., Machado, F. R., Montravers, P., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05599-w · Cited by 235
“Candida species biomarkers (especially BDG) are now increasingly being used to enable earlier diagnosis of IC [53].”
MethodThe Cava Trem Study Group, León, C., Ruiz-Santana, S., Saavedra, P., Castro, C., Loza, A., Zakariya, I., Úbeda, A., Parra, M., Macías, D., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1324-3 · Cited by 110
“[31] showed that the presence of a positive CAGTA test in a sample from a patient with candidemia suggests deepseated candidiasis, and more recently, provided evidence that the combination of CAGTA and BDG, or CAGTA and mannan-Ag, had high negative predictive values [32].”
ResultThe current treatment landscape: Candidiasis
Bassetti, M., Peghin, M., & Timsit, J.-F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw392 · Cited by 99
Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients
Giacobbe, D. R., Del Bono, V., Viscoli, C., & Mikulska, M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1401467 · Cited by 27
Metadata
- Authors
- Martínez-Jiménez, M. C., Muñoz, P., Valerio, M., Alonso, R., Martos, C., Guinea, J., & Bouza, E.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-21
- Volume
- 70
- Issue
- 8
- Pages
- 2354-2361
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2115921930
- Cited by
- 65
- References
- 8
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.